Your browser doesn't support javascript.
loading
Analysis and Suggestions on the Development of Biomedical Industry in Guangdong-Hong Kong-Macao Greater Bay Area / 中国药房
China Pharmacy ; (12): 2566-2574, 2021.
Article in Chinese | WPRIM | ID: wpr-904512
ABSTRACT
OBJECTIVE:To provide reference for furthe r promoting the high-quality development of the biomedical industry in Guangdong-Hong Kong-Macao Greater Bay Area. METHODS :Through summarizing the development status and development environment of the biomedical industry in the Guangdong-Hong Kong-Macao Greater Bay Area ,the construction experience of foreign advanced biomedical industrial park was introduced ,and the problems and challenges faced by the biomedical industry in the Guangdong-Hong Kong-Macao Greater Bay Area were sorted out so as to put forward relevant countermeasures and suggestions. RESULTS & CONCLUSIONS :Guangdong-Hong Kong-Macao Greater Bay Area has received multiple policy support,which is conducive to the development of biomedical industry. The industrial chain is complete ,and the scale advantage of biological industry is showing day by day. Biological industry has achieved fruitful innovation achievement ,and its R&D investment is in the leading position in the country. The pharmaceutical manufacturing industry is developed and the total amount of medical resources is large. The financial advantages are obvious ,and institutional innovation is conducive to the development of biomedical industry. The process of internationalization takes the leading place ,which is conducive to continuously promoting foreign cooperation. However ,compared with foreign advanced biomedical industrial parks ,Guangdong-Hong Kong-Macao Greater Bay Area still has some deficiencies in management mode ,service mode and “industry-university-institute”cooperation. It also faces the following problems that the legal systems and industry norms of the three places need to be further connected ;there is a talent gap ;the industrial chain is not perfect ;the support for new drug R&D is insufficient ;the“industry-university-institute” cooperation needs to be strengthened ;the level of financial support needs to be improved. Accordingly ,it is recommended to break down institutional barriers ,and promote the connection between the legal system and industry norms ;innovate talent policies ,and continue to attract excellent R&D talents ;introduce leading companies ,and improve the industrial chain ;open up clinical trial channels and promote the transformation efficiency of scientific research achievements ;strengthen“industry-university-institute” cooperation,and promote the improvement of biomedical innovation ability ;make good use of financial support to help the rapid rise of biomedical industry enterprises ,so as to promote the high-quality development of biomedical industry in Guangdong-Hong Kong-Macao Greater Bay Area.

Full text: Available Index: WPRIM (Western Pacific) Language: Chinese Journal: China Pharmacy Year: 2021 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Language: Chinese Journal: China Pharmacy Year: 2021 Type: Article